Journals / The Anatolian Journal of Cardiology / 2020 / Cilt: 23 - Sayı: 3

Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality

Pages
160–168
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

SELFIE-TR is a registry illustrating the overall HF patient profile of Turkey.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Heart failure (HF) is a progressive clinical syndrome.
📊
Key Findings & Data:Patients were classified as acute HF (AHF) versus chronic HF (CHF) and HF withreduced ejection fraction (HFrEF), HF with mid-range ejection fraction, and HF with preserved ejection fraction and were followed up for ACM.Results: There were 1054 patients with a mean age of 63.3±13.3 years and with a median follow-up period of 16 (7–17) months.
💡
Conclusion & Impact:SELFIE-TR is a registry illustrating the overall HF patient profile of Turkey.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Heart failure (HF) is a progressive clinical syndrome. SELFIE-TR is a registry illustrating the overall HF patient profile of Turkey. Herein,all-cause mortality (ACM) data during follow-up were provided.Methods: This is a prospective outcome analysis of SELFIE-TR. Patients were classified as acute HF (AHF) versus chronic HF (CHF) and HF withreduced ejection fraction (HFrEF), HF with mid-range ejection fraction, and HF with preserved ejection fraction and were followed up for ACM.Results: There were 1054 patients with a mean age of 63.3±13.3 years and with a median follow-up period of 16 (7–17) months. Survival datawithin 1 year were available in 1022 patients. Crude ACM was 19.9% for 1 year in the whole group. ACM within 1 year was 13.7% versus 32.6%in patients with CHF and AHF, respectively (p<0.001). Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta blocker, andmineralocorticoid receptor antagonist were present in 70.6%, 88.2%, and 50.7%, respectively. In the whole cohort, survival curves were gradedaccording to guideline-directed medical therapy (GDMT) scores ≤1 versus 2 versus 3 as 28% versus 20.2% versus 12.2%, respectively (p<0.001).Multivariate analysis of the whole cohort yielded age (p=0.009) and AHF (p=0.028) as independent predictors of mortality in 1 year.Conclusion: One-year mortality is high in Turkish patients with HF compared with contemporary cohorts with AHF and CHF. Of note, GDMT scoreis influential on 1-year mortality being the most striking one on chronic HFrEF. On the other hand, in the whole cohort, age and AHF were the onlyindependent predictors of death in 1 year

🔖

Cite This Article

YILMAZ, M. B., AKSAKAL, E., AKSU, U., ALTAY, H., YILDIRIM, N., ÇELİK, A., AKIL, M. A., BEKAR, L., VURAL, M. G., GÜVENÇ, R. Ç., ÖZER, S., URAL, D., ÇAVUŞOĞLU, Y., TOKGÖZOĞLU, L. (2020). Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. The Anatolian Journal of Cardiology, Cilt: 23 - Sayı: 3, 160–168. https://ajindex.com/articles/365677

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Değertekin M, Erol C, Ergene O, Tokgözoğlu L, Aksoy M, Erol MK, et al. Heart failure prevalence and predictors in Turkey: HAPPY study. Turk Kardiyol Dern Ars 2012; 40: 298-308
  2. Tokgözoğlu L, Kayıkçıoğlu M, Altay S, Aydoğdu S, Barçın C, Bostan C, et al. [EUROASPIRE-IV: European Society of Cardiology study of lifestyle, risk factors, and treatment approaches in patients with coronary artery disease: Data from Turkey]. Turk Kardiyol Dern Ars 2017; 45: 134-44
  3. Yılmaz MB, Çelik A, Çavuşoğlu Y, Bekar L, Onrat E, Eren M, et al. Snapshot evaluation of heart failure in Turkey: Baseline characteristics of SELFIE-TR. Turk Kardiyol Dern Ars 2019; 47: 198-206
  4. Zoghi M, Kaya H, Çavuşoğlu Y, Aksakal E, Demir Ş, Yücel C, et al. Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. Turk Kardiyol Dern Ars 2016; 44: 457-65
  5. Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Pannaux M, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail 2018; 20: 1315-22
  6. Balakumaran K, Patil A, Marsh S, Ingrassia J, Kuo CL, Jacoby DL, et al. Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction. Int J Cardiol Heart Vasc 2018; 22: 1-5
  7. Fiuzat M, Sbolli M, Cani DS, O'Connor C, Abraham W, Psotka M, et al. Guideline Directed Medical Therapy in Heart Failure Trials: A New Proposed Scoring System. Journal of Cardiac Failure 2019; 25: S77
  8. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137-46
  9. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004; 25: 1614-9
  10. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, et al.; EPICA Investigators. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 2002; 4: 531-9
  11. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208-25
  12. Mosterd A, Reitsma JB, Grobbee DE. Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Net